Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Nepstar Looks To Expansion, Private-Label Program As Stock Plunges

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's largest drugstore chain China Nepstar added 244 more stores to its growing empire of drugstores in the second quarter of 2008 and began centralizing its purchases to cut down on costs

You may also be interested in...



China’s State FDA, Security Ministry, Olympics Organizers Launch Joint Crackdown On Performance Enhancers During Summer Games

BEIJING - Since the run-up to to Beijing's first staging of the Olympic Games, China's State FDA has broadly publicized its campaign to halt the illicit sale of performance-enhancing drugs and biologics across the country, but the agency's task is complicated by Internet sales

China Nepstar Signs 16 Cooperative Agreements With Multinational, Domestic Partners

SHANGHAI - China Nepstar Chain Drugstore signed strategic cooperative agreements with 16 pharmaceutical and health products suppliers as part of its store network expansion plan for 2008, the drugstore chain announced Dec. 14

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel